Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
25 – 55
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
70 (estimated)
Sponsor
Emory University · Other
Who this trial is looking for
This trial is looking for people aged 25 to 55 with depression and high inflammation who feel little joy in life. Participants will take either L-DOPA or a placebo for 8 weeks and will undergo various tests and scans during the study.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 25 and 55 years old
I have been diagnosed with depression
I have a high level of inflammation
I feel little pleasure in life
I can give written consent
I am not currently taking any antidepressants for at least 4 weeks
I have a PHQ-9 score over 10
I have a CRP level of 2 mg/L or higher
You may not be able to join if
I have an autoimmune disorder
I have a history of hepatitis B or C or HIV
I have had any type of cancer that needed treatment
I have unstable health issues in my heart, liver, or brain
I have a history of a psychotic disorder or bipolar disorder
I have an active plan to harm myself
I have an eating disorder (unless it's binge eating that's linked to mood problems)
I am pregnant or breastfeeding
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete…
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* a. willing and able to give written informed consent
* b. men or women, 25-55 years of age
* c. a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), current, as diagnosed by the Structured Clinical Interview for DSM-5
* d. score …
Inclusion Criteria:
* a. willing and able to give written informed consent
* b. men or women, 25-55 years of age
* c. a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), current, as diagnosed by the Structured Clinical Interview for DSM-5
* d. score of \>10 on the Patient Health Questionnaire-9 (PHQ-9) or HAM-D score ≥18
* e. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine)
* f. c-reactive protein (CRP) ≥2 mg/L
* g. PHQ-9 anhedonia score ≥2
Exclusion Criteria:
* a. history or evidence (clinical or laboratory) of an autoimmune disorder
* b. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
* c. history of any type of cancer requiring treatment with more than minor surgery
* d. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing)
* e. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; history or current bipolar disorder; history or current gambling disorder; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview)
* f. active suicidal plan as determined by a score \>3 on item #3 on the HAM-D
* g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms)
* h. a history of a cognitive disorder or traumatic head injury involving loss of consciousness
* i. pregnancy or lactation
* j. use of gender affirming hormone therapy
* k. chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), glucocorticoid containing medications or statins
* l. use of NSAIDS, glucocorticoids, or statins at any time during the study
* m. urine toxicology screen is positive for drugs of abuse, n. any contraindication for MRI scanning
* o. intolerance, sensitivity or contraindication to carbidopa-levodopa (including history of narrow-angle glaucoma, melanoma, gastric and/or duodenal ulcers, bleeding disorders, or frequent migraines)
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.